| 海西特區 藥材登陸轉運站 |
| |
| 【2010/11/18 經濟日報】第六次江陳會將近，兩岸醫藥合作傳出新變化，大陸國家食品藥品監督管理局（SFDA）將以福建海西地區為先試、先行市場，此舉將帶動國內藥品、醫材、保健品及中草藥有機會外銷到當地市場。 生技股昨（17）日大漲，年底召開的第六次江陳會也成為市場關注焦點，已在中國布局多時，正將進入收割的中化、杏輝、佳醫、杏昌、東洋、晟德、太醫、中天、聯合等公司都有機會收惠。 協助推動醫藥合作的生策會表示，江陳會將洽談項目，包括新藥、醫材及中草藥三領域，雙方將簽署「醫藥衛生合作協議」，但目前大陸希望僅就大架構建立共識，台灣則期待簽署更多細項合作協議。 不過，福建省藥監局副局長張炳祥公開表示，福建省已和中央達成協議，兩岸醫藥的相互探討，將由福建省為主的海西地區，做為先試、先行、先准的試辦區。
|
中天龍潭廠獲經濟部頒發觀光工廠標章
2010-11-18 08:57 時報資訊 【中天生技(4128)龍潭廠榮獲經濟部頒發觀光工廠標章。中天龍潭廠配合政府政策及資產活化目標，委請專家規劃為第一流的觀光工廠，並於本月17日獲經濟部頒發觀光工廠標章。 中天龍潭觀光工廠係結合gmp藥廠、gmp食品廠、綠建築、自然生態園區共約萬餘坪，形成為融合有機、環保、健康等三大訴求的觀光園區。中天表示，公司各關係企業基於推動環保與自然健康之概念，自2007年起即規畫投入有機、環保、健康等事業領域，已陸續獲得政府「有機農產品驗證機構」認證、iso17025龍潭廠實驗室認証、觀光工廠標章、及建立棉花田生機產品連鎖門市，垂直整合發展有機、綠色、環保、健康等事業體系。
證交所重大訊息公告
1.事實發生日:2010/11/17
2.本次新增（減少）投資方式:增資子公司O'Long Enterprises(B.V.I)，再由O'Long轉投資孫公司永光製藥有限公司(北京)美金250萬。
3.交易數量、每單位價格及交易總金額:總金額美金250萬元。
4.本次新增投資大陸被投資公司之公司名稱:永光製藥有限公司(北京)
5.前開大陸被投資公司之實收資本額:USD982萬
6.前開大陸被投資公司本次擬新增資本額:USD250萬
7.前開大陸被投資公司主要營業項目:經營藥品醫療保健品等
8.前開大陸被投資公司最近年度財務報表會計師意見型態:修正式無保留
9.前開大陸被投資公司最近年度財務報表淨值:RMB-1,213仟元
10.前開大陸被投資公司最近年度財務報表損益金額:RMB-4,165仟元
11.迄目前為止，對前開大陸被投資公司之實際投資金額:NT$227,127仟元
12.迄目前為止，投審會核准赴大陸地區投資總額（含本次投資）:NT$536,527 仟元
13.迄目前為止，投審會核准赴大陸地區投資總額（含本次投資）占最近期財務報表實收資本額之比率:61.61 %
14.迄目前為止，投審會核准赴大陸地區投資總額（含本次投資）占最近期財務報表總資產之比率:27.98 %
15.迄目前為止，投審會核准赴大陸地區投資總額（含本次投資）占最近期財務報表股東權益之比率:31.86 %
16.迄目前為止，實際赴大陸地區投資總額:NT$275,622 仟元
17.迄目前為止，實際赴大陸地區投資總額占最近期財務報表實收資本額之比率:31.65 %
18.迄目前為止，實際赴大陸地區投資總額占最近期財務報表總資產之比率:14.37 %
19.迄目前為止，實際赴大陸地區投資總額占最近期財務報表股東權益之比率:16.37 %
20.最近三年度認列投資大陸損益金額:
96年：投資損失NT$ 5,680仟元
97年：投資損失NT$ 9,931仟元
98年：投資損失NT$ 26,008仟元
21.最近三年度獲利匯回金額:0
22.交易相對人及其與公司之關係:不適用。
23.交易相對人為實質關係人者，並應公告選定關係人為交易對象之原因及前次移轉之所有人（含與公司及相對人間相互之關係）、移轉日期及金額:不適用。
24.交易標的最近五年內所有權人曾為公司之實質關係人者，尚應公告關係人之取得及處分日期、價格及交易當時與公司之關係:不適用。
25.處分利益（或損失）:不適用。
26.交付或付款條件（含付款期間及金額）、契約限制條款及其他重要約定事項:投資美金250萬元。
27.本次交易之決定方式、價格決定之參考依據及決策單位:經董事會決議。
28.經紀人:無。
29.取得或處分之具體目的:長期投資及拓展大陸事業。
30.本次交易董事有異議:否
31.本次交易會計師出具非合理性意見:否
China Entices Scientists to Return Home
WSJ; NOVEMBER 17, 2010,BEIJING—After eight years working in the U.S. at the National Institutes of Health, a major federal research center, cell biologist Li Yu decided in 2008 it was time to return to his native China and became a professor here at Tsinghua University.Dr. Yu is one of some 80,000 Western-trained Chinese scientists who have returned to China to work in academia or industry since the mid-1980s. In a report published Wednesday, the Monitor Group, a consultancy, predicts the return will accelerate over the next decade, and says the trend, coupled with an outpouring of investment by the Chinese government and private industry, will help China become a leader in research discovery in the pharmaceutical and health-care industry by 2020.A professor at Tsinghua University places a note among bottles of bacterial culture in a university lab in Beijing in June. China is ramping up efforts to attract top scientists who have been trained in the U.S. China is already the third-largest pharmaceutical market and is expected to grow by 25% to more than $50 billion in sales in 2011, according to drug-industry tracker IMS Health. But until recently, the West was the source of innovation in the industry.
"I think the big call to arms … is that the world is going to change, and China is going to be on many levels the leader, including life science innovation," says George Baeder, head of Monitor Group's life sciences practice in Asia and an author of the report. China is making a concerted effort to become a research powerhouse by drawing researchers back home. Two years ago, the government launched the "Thousand Talents" program with the goal of bringing back 2,000 scientists over five to 10 years by promising resources and funding, according to the Chinese Academy of Sciences. Monitor Group says the program has offered qualified returning scientists up to 10 million yuan, or $1.5 million, each in resources and funding. Beijing also offers a variety of other funds to help academics and entrepreneurs kick off their work. China still has far to go to attain the overall level of research in places like the U.S. and Europe, and a variety of issues could impede its progress. China has yet to spawn a major global pharmaceutical company that develops its own products. China's research sector also struggles with procedural problems and fraud that render its research unusable for other scientists. Mr. Baeder says fundamental cultural changes, such as moving to a merit-based system of funding from one based mostly on who one knows, will be important to the country's progress in innovation. Some U.S. scientists and officials have been concerned that difficulty in securing federal grants for research—the primary mechanism by which much science research is funded in America—may be driving young scientists away from academia and basic science research. U.S. universities remain the most attractive in the world for Chinese and other foreign students in the sciences. China surpassed India last year as the biggest source of foreign students in U.S. institutions of higher education with 127,628, up 30% from the year before. But keeping Chinese scientists in the U.S. once they are trained is increasingly difficult. Dr. Yu, the former NIH researcher, was drawn back by the scientific possibilities in China that he feels aren't possible in the U.S. His large lab full of students, along with essentially unlimited research funds guaranteed to him by the government and the university, has allowed him to accelerate his work. As a result, he has been able to expand his basic-science research and think about applying it to the treatment of diseases such as neurodegenerative and autoimmune conditions. "The bottom line, I think, is we just get a better opportunity" in China, said Dr. Yu. "In China, anything can happen." For S. Benjamin Hua, an entrepreneurial spirit called him back to China after 20 years. He left in 1986 when the government paid for him to get his doctorate at the University of Maryland. Back then, people in China had "just heard about" biomedical research, Dr. Hua says, and going to the U.S. for training was seen as an opportunity and necessary step. He returned to China in 2007 because of the opportunity to launch a new company in a growing market, armed with the knowledge from his academic training at Maryland and the University of California, San Francisco, and from the biotechnology industry in Silicon Valley. Although his family remains in the U.S., and he travels frequently between the two countries, he felt he had to live in China to better understand and succeed in the Chinese market. Last year, Dr. Hua launched Hangzhou Avalon Biosciences, a clinical diagnostics company focused on infectious diseases and cancer, which has grown to 12 employees. Many of his peers are also returning to China, he says. For many, the language and cultural barriers in the U.S. mean expending extra effort to achieve the same level of success as native speakers. The erasing of that barrier with a return to China, coupled with the government's support, is appealing, he said.
China's goal "is to change from 'made in China' to 'innovated in China,' " Dr. Hua said.